GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.

STUDY QUESTION Does a GnRH agonist (GnRHa) trigger followed by a bolus of 1.500 IU hCG in a group of patients at risk of ovarian hyperstimulation syndrome (OHSS) reduce the OHSS incidence compared with hCG trigger? SUMMARY ANSWER A GnRHa trigger followed by early luteal hCG support with one bolus of 1.500 IU hCG appears to reduce OHSS in patients at risk of OHSS; however, in a low-risk group a second bolus of 1.500 IU hCG induced two cases of late onset OHSS. WHAT IS KNOWN ALREADY A GnRHa trigger is an alternative to hCG in GnRH antagonist co-treated cycles. STUDY DESIGN, SIZE, DURATION Two RCTs were performed in four Danish IVF units. A total of 446 patients were assessed for eligibility and 390 patients were enrolled in the study from January 2009 until December 2011. The primary outcome of the study was OHSS incidence in the group at risk of OHSS. PARTICIPANTS/MATERIALS, SETTING, METHODS Patients received a fixed dose of recombinant human FSH for the first 4 days. On the day of triggering, patients were assessed for their risk of OHSS based on the total number of follicles ≥11 mm diameter, and were classified as being at risk of OHSS when the total number of follicles ≥11 mm was between 15 and 25 and at low risk of OHSS when the total number of follicles ≥11 mm was ≤14. Two separate randomization lists were used for each of the OHSS risk groups. Women at risk of OHSS were allocated (RCT 1) to either: Group A (n = 60), ovulation triggering with a bolus of 0.5 mg buserelin (GnRHa) s.c. followed by a single bolus of 1.500 IU hCG s.c. after the oocyte retrieval-or: Group B (n = 58): 5.000 IU hCG. Similarly, women at low risk of OHSS were allocated (RCT 2) to receive either: Group C (n = 125), a bolus of 0.5 mg buserelin s.c., followed by a bolus of 1.500 IU hCG s.c. after oocyte retrieval and a second bolus of 1.500 IU hCG on the day of oocyte retrieval +5-or: Group D (n = 141), 5.000 IU hCG. Groups C and D were included in order to obtain preliminary data. MAIN RESULTS AND THE ROLE OF CHANCE In women at risk of OHSS (RCT 1) (15-25 follicles) no OHSS case was seen in Group A (GnRHa trigger and one bolus of 1.500 IU hCG), whereas two cases of moderate late-onset OHSS occurred in group B (3.4%), (P = 0.24). In contrast, in women at a low risk of OHSS (RCT 2) (≤14 follicles) two cases of late-onset OHSS occurred in Group C (GnRHa trigger and two boluses of 1.500 IU hCG), whereas no OHSS case was encountered in Group D (P = 0.22). LIMITATIONS, REASONS FOR CAUTION Although the first RCT was powered to include 168 patients at risk of OHSS (15-25 follicles ≥11 mm) randomized to either GnRHa trigger or hCG trigger, the trial was prematurely discontinued when a total of 118 patients at risk of OHSS were randomized. In addition the second RCT in the OHSS low-risk group was designed as a feasibility study to assess the incidence of OHSS after GnRHa trigger and dual hCG administration versus 5.000 IU hCG. No power calculation was performed for this trial. In addition, there was a lack of blinding in the RCTs. WIDER IMPLICATIONS OF THE FINDINGS Although a non-significant result, one bolus of 1.500 IU hCG after GnRHa trigger tended to reduce the OHSS rate in patients with 15-25 follicles ≥11 mm as well as secure the ongoing pregnancy rate. In contrast, in patients at low risk of OHSS the administration of two boluses of 1.500 IU hCG after GnRHa trigger should be avoided as it may induce OHSS.

[1]  J. Nulsen,et al.  The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. , 2008, Fertility and sterility.

[2]  H. Tournaye,et al.  A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. , 2011, Fertility and sterility.

[3]  M. Eijkemans,et al.  Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with rec , 2003, The Journal of clinical endocrinology and metabolism.

[4]  L. Westergaard,et al.  Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction. , 1993, Human reproduction.

[5]  H. Tournaye,et al.  Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. , 2006, Fertility and sterility.

[6]  E. Papanikolaou,et al.  GnRH agonist for triggering of final oocyte maturation: time for a change of practice? , 2011, Human reproduction update.

[7]  E. Anteby,et al.  Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols. , 2006, Reproductive biomedicine online.

[8]  K. Tremellen,et al.  Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. , 2011, Human reproduction.

[9]  P. Humaidan,et al.  Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. , 2006, Reproductive biomedicine online.

[10]  Y. Soong,et al.  Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  R. Casper,et al.  Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. , 1979 .

[12]  N. Laufer,et al.  Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment , 1993 .

[13]  D. Wolf,et al.  Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. , 1996, Human reproduction.

[14]  C. Andersen.  Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. , 2002 .

[15]  N. Sugino,et al.  Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  P. Devroey,et al.  The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. , 2012, Reproductive biomedicine online.

[17]  P. Humaidan.  Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. , 2009, Reproductive biomedicine online.

[18]  J. Tesarik,et al.  Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. , 2006, Human reproduction.

[19]  A. Byskov,et al.  FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. , 1999, Molecular human reproduction.

[20]  R. Orvieto.  Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? , 2012, Reproductive biomedicine online.

[21]  L. Wildt,et al.  On the Role of Human Chorionic Gonadotropin (hCG) in the Embryo-Endometrial Microenvironment: Implications for Differentiation and Implantation , 2001, Seminars in reproductive medicine.

[22]  P. Humaidan,et al.  Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. , 2006, Human reproduction.

[23]  J. Eppig.  FSH stimulates hyaluronic acid synthesis by oocyte–cumulus cell complexes from mouse preovulatory follicles , 1979, Nature.

[24]  F. Bonilla-musoles,et al.  Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. , 2010, Reproductive biomedicine online.

[25]  R. Feinn,et al.  Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. , 2011, Fertility and sterility.

[26]  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. , 2004, Fertility and sterility.

[27]  P. Devroey,et al.  An OHSS-Free Clinic by segmentation of IVF treatment. , 2011, Human reproduction.

[28]  P. Claman.  Men at risk: occupation and male infertility. , 2004, Fertility and sterility.

[29]  M. Huleihel,et al.  Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. , 2006, Human reproduction.

[30]  S. Yen,et al.  Hormonal dynamics at midcycle: a reevaluation. , 1983, The Journal of clinical endocrinology and metabolism.

[31]  S. Strickland,et al.  Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins. , 1976, The Journal of biological chemistry.

[32]  T. Imbar,et al.  Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. , 2012, Human reproduction.

[33]  L. Engmann,et al.  Intensive luteal phase support after GnRH agonist trigger: it does help. , 2012, Reproductive biomedicine online.

[34]  P. Humaidan,et al.  1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. , 2010, Fertility and sterility.

[35]  O. P. Bahl,et al.  Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin. , 1979, The Journal of biological chemistry.

[36]  L. Kahana,et al.  Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. , 1991, Fertility and sterility.

[37]  L. Engmann,et al.  GnRH agonist (buserelin) or HCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. , 2005, Human reproduction.

[38]  R. Casper,et al.  Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. , 1990, The Journal of clinical endocrinology and metabolism.

[39]  L. Engmann,et al.  Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. , 2012, Fertility and sterility.

[40]  J. Balasch.  Correction to “Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249-61.” , 1993 .

[41]  Z. Shoham,et al.  Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. , 1996, Human reproduction.

[42]  E. Kolibianakis,et al.  Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. , 2007, Human reproduction.

[43]  D. Wolf,et al.  Endocrinology: Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys , 1995 .

[44]  P. Humaidan,et al.  Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. , 2011, Fertility and sterility.

[45]  S. Daneshmand,et al.  Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. , 2008, Fertility and sterility.

[46]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[47]  C. Yding Andersen.  Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. , 2002, Reproductive biomedicine online.

[48]  S. Daneshmand,et al.  Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. , 2011, Fertility and sterility.